A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Colloids and Surfaces B: Biointerfaces

• Publication date

  2014-10-01

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1016/j.colsurfb.2014.07.045PMID 25139293
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proprotein Convertase Subtilisin/Kexin 9 Inhibitors

  2015cited by this paper
• Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies

  2014cited by this paper
• An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report.

  2014cited by this paper
• Recent advances in pharmacotherapy for hypertriglyceridemia.

  2014cited by this paper
• Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue

  2014cited by this paper
• Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression

  2014cited by this paper
• Curcuminoids for the management of hypertriglyceridaemia

  2014cited by this paper
• HDL: To Treat or Not To Treat?

  2014cited by this paper
• Role of selective peroxisome proliferator‐activated receptor modulators in managing cardiometabolic disease: tale of a roller‐coaster

  2014cited by this paper
• Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. is there a need to change our approach to diagnosing dyslipidemia?

  2014cited by this paper
• New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

  2014cited by this paper
• New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

  2013cited by this paper
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

  2013cited by this paper
• An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.

  2013cited by this paper
• Fat lowers fat: purified phospholipids as emerging therapies for dyslipidemia.

  2013cited by this paper
• New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

  2013cited by this paper
• Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum.

  2013cited by this paper
• Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

  2013cited by this paper
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)

  2012cited by this paper
• Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

  2012cited by this paper
• Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

  2012cited by this paper
• Lipid-lowering therapies and achievement of LDL-cholesterol targets

  2012cited by this paper
• Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.

  2011cited by this paper
• Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits

  2010cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.

  2009cited by this paper
• Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery.

  2009cited by this paper
• Lipoprotein Management in Patients With Cardiometabolic Risk

  2008cited by this paper
• Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.

  2008cited by this paper
• Liposomes in biology and medicine.

  2007cited by this paper
• Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies.

  2007cited by this paper
• Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.

  2007cited by this paper
• Cardiovascular Diabetology BioMed Central Review

  2006cited by this paper
• Liposome Opsonization

  2005cited by this paper
• Recent advances with liposomes as pharmaceutical carriers

  2005cited by this paper
• Marked low‐density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis

  2004cited by this paper
• Phosphatidylinositol promotes cholesterol transport and excretion Published, JLR Papers in Press, April 16, 2003. DOI 10.1194/jlr.M300062-JLR200

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

  2003cited by this paper
• hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.

  2003cited by this paper
• Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr.

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• LDL Induced Association of Anionic Liposomes with Cells and Delivery of Contents as Shown by the Increase in Potency of Liposome Dependent Drugs

  2001cited by this paper
• Phosphatidylinositol promotes cholesterol transport in vivo.

  2000cited by this paper
• Structural and metabolic consequences of liposome-lipoprotein interactions.

  1998cited by this paper
• Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles.

  1998cited by this paper
• Aggregation of dimyristoylphosphatidylglycerol liposomes by human plasma low density lipoprotein.

  1998cited by this paper
• The NH2-terminal Region of Apolipoprotein B Is Sufficient for Lipoprotein Association with Glycosaminoglycans*

  1998cited by this paper
• Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

  1998cited by this paper
• The Class B Scavenger Receptors SR-BI and CD36 Are Receptors for Anionic Phospholipids (*)

  1995cited by this paper
• Association of negatively-charged phospholipids with low-density lipoprotein (LDL) increases its uptake and the deposition of cholesteryl esters by macrophages.

  1995cited by this paper
• By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

  1994cited by this paper
• Fate and behavior of liposomes in vivo: a review of controlling factors.

  1987cited by this paper
• A receptor-mediated pathway for cholesterol homeostasis.

  1986cited by this paper
• Foam Cells in Explants of Atherosclerotic Rabbit Aortas Have Receptors for β‐Very Low Density Low Density Lipoproteins and Modified Low Density Lipoproteins

  1983cited by this paper
• Phosphorus assay in column chromatography.

  1959cited by this paper

• Nanotechnology and Artificial Intelligence in Dyslipidemia Management—Cardiovascular Disease: Advances, Challenges, and Future Perspectives

  2025cites this paper
• Preparation and evaluation of 111In-labeled liposomes containing phosphatidylglycerol for detection of macrophages in atherosclerotic plaques.

  2023cites this paper
• Enhanced Therapeutic Effect of Liposomal Doxorubicin via Bio-Orthogonal Chemical Reactions in Tumors.

  2022cites this paper
• Preclinical toxicity assessment of anionic nanoliposomes

  2022cites this paper
• Phosphatidylserine-containing liposomes: Therapeutic potentials against hypercholesterolemia and atherosclerosis.

  2021cites this paper
• Negatively-charged liposome nanoparticles can prevent dyslipidemia and atherosclerosis progression in the rabbit model.

  2021cites this paper
• A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome.

  2020cites this paper
• A simple and rapid-acting approach for the reduction of C-reactive protein.

  2019cites this paper
• Anionic nanoliposomes reduced atherosclerosis progression in Low Density Lipoprotein Receptor (LDLR) deficient mice fed a high fat diet

  2018cites this paper
• Liposomes Containing Gadodiamide: Preparation, Physicochemical Characterization, and In Vitro Cytotoxic Evaluation.

  2017cites this paper
• Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia.

  2015cites this paper